Triptorelin
- Category
- Hormone & Sexual Health
- Administration routes
- Injectable
- Regulatory status
- FDA-approved
What it is
A synthetic GnRH agonist that suppresses testosterone or estrogen to castrate levels after an initial hormone surge. Human evidence is strong: it is an established treatment for advanced prostate cancer, endometriosis, precocious puberty, and IVF ovarian suppression. Real risks include the initial tumor flare, meaningful bone density loss, hot flashes, and sexual dysfunction. It is an FDA-approved prescription drug, not a longevity or wellness product.
Read Full recordStudied uses & evidence
Studied uses(5)
Effective androgen deprivation in advanced prostate cancer
HighFDA-approved; randomized trial showed non-inferiority to leuprolide, backed by Cochrane review.
Reduction of endometriotic lesions and pain symptoms
HighPlacebo-controlled and post-surgical randomized trials show reduced pelvic pain and lesion severity.
Suppression of precocious puberty in children
MediumOpen-label pediatric trials show hormone suppression; no placebo-controlled study exists for ethical reasons.
Evidence limits
- Evidence Level
- Level 1 — FDA Approved
Triptorelin has one of the strongest evidence bases among peptide therapeutics, with Level I evidence across its primary indications. In prostate cancer, the EORTC 22961 trial (1,113 registered; 970 randomized; published in NEJM) is the cornerstone study demonstrating survival benefit for long-term ADT with triptorelin. This is supported by multiple Phase III trials demonstrating consistent testosterone suppression, a multicenter RCT confirming equivalence to surgical castration, and large-scale pharmacovigilance data from decades of post-marketing use. In endometriosis, the Bergqvist 1998 double-blind placebo-controlled RCT provides Level I evidence for lesion reduction and symptom control. In CPP, multiple Phase III trials and a meta-analysis support triptorelin's efficacy in achieving prepubertal hormone suppression. In IVF, triptorelin is an established standard-of-care agent for pituitary downregulation, supported by numerous RCTs. Safety is well-characterized through decades of clinical experience and FAERS pharmacovigilance analysis. Overall, triptorelin's evidence base is mature and robust — it is not an experimental peptide but a well-established pharmaceutical.
Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Cautions & risk summary
Do not use if
Undiagnosed vaginal bleeding
AbsoluteMust rule out malignancy before starting GnRH agonist therapy.
Osteoporosis (severe)
HighLong-term use causes bone density loss through sex hormone suppression.
General cautions
Pregnancy
AbsoluteFDA contraindication. Can cause fetal harm and spontaneous abortion.
Risk summary(9)
Risks = level of concern: High · Moderate · Low · Theoretical
Tumor flare (initial hormone surge)
HighCardiovascular events (MI, stroke, sudden cardiac death)
ModerateQT prolongation and torsade de pointes
LowBone mineral density loss and fracture risk
HighMetabolic effects (hyperglycemia, diabetes, dyslipidemia)
ModerateHot flashes and vasomotor symptoms
HighSexual dysfunction and loss of libido
HighSeizures and neuropsychiatric effects
LowPregnancy exposure (teratogenicity)
High
Further reading
- Overview in Full record
- Safety & interactions in Full record
- Research & benefits in Full record
- Prescribing labels in Full record
- Monitoring & labs in Full record
- Regulation & availability in Full record
- Sources in Full record
- Frequently asked questions in Full record
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.